IN8bio
INAB
26 hedge funds and large institutions have $6.77M invested in IN8bio in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 9 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0.08% less ownership
Funds ownership: 0.67% → 0.58% (-0.08%)
19% less funds holding
Funds holding: 32 → 26 (-6)
34% less capital invested
Capital invested by funds: $10.2M → $6.77M (-$3.45M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$209K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$90.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$55.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.4K |
| 5 |
State Street
Boston,
Massachusetts
|
+$31.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$799K |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$249K |
| 3 |
Renaissance Technologies
New York
|
-$141K |
| 4 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
-$106K |
| 5 |
Two Sigma Investments
New York
|
-$49K |
INAB Hedge Fund Activity: Q2 2024 in Review
26 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q2 2024, worth a combined $6.77M — down 34% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of INAB and 3 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Alyeska Investment Group, adding an estimated $209K. The largest seller was AIGH Capital Management, cutting an estimated $799K.
- 26 institutional investors held IN8bio (INAB) as of Q2 2024, down from 32 in Q1 2024.
- Funds reported $6.77M of IN8bio stock for Q2 2024, down 34% quarter-over-quarter.
- 3 funds opened new IN8bio positions in Q2 2024 and 9 closed out, a net change of -6 holders.
- The largest IN8bio buyer in Q2 2024 was Alyeska Investment Group, an estimated $209K added.
- The largest IN8bio seller in Q2 2024 was AIGH Capital Management, an estimated $799K sold.
Based on aggregated 13F filings for Q2 2024.